AVX pharma announces initiation of a Phase 2 Clinical Trial of AVX-012 Ophthalmic Solution in Dry Eye Syndrome Blog Post

Avizorex Pharma (AVX Pharma), a clinical stage biopharmaceutical company with offices at Barcelona Science Park and focused on the development of novel therapies for Dry Eye Syndrome, today announced the initiation of a Phase 2 clinical trial, evaluating the safety and efficacy of AVX-012 Ophthalmic Solution in patients with mild-to-moderate Dry Eye Syndrome, based on the concept of modulating corneal nerve activity to stimulate basal lacrimation.

 

The Institute for Bioengineering of Catalonia joins BIST Foundation Blog Post

The Board of the Barcelona Institute of Science and Technology (BIST) has approved the incorporation of the Institute for Bioengineering of Catalonia (IBEC) –based at the Barcelona Science Park– as a new member. At its annual meeting held today in Barcelona, the Board has also appointed Gabriel M. Silberman as a new BIST general director, replacing Miquel A. Pericàs, director of the Institute of Chemical Research of Catalonia (ICIQ).

 

Boosting natural detoxification pathways in the body to reduce cellular oxidative stress Blog Post

Promoting innate detoxification mechanisms in the body and discovering which supplements increase the efficacy of those biochemical pathways could be an efficient strategy to reduce the cellular oxidative stress and protect our health, according to an article published in the journal Food Chemistry, by the researchers Rafael Franco, from the Institute of Biomedicine of the University of Barcelona at the Barcelona Science Park and Eva Martínez Pinilla, from the Institute of Neurosciences of Asturias (INEUROPA) and the University of Oviedo.

 

Esteve co-leads international consortium for the development of more efficacious therapies for neuropathic pain Blog Post

Esteve at the Barcelona Science Park co-leads the NGN-PET consortium, that unites the expertise and knowledge of industry partners from the European Federation of Pharmaceutical Industries and Associations (EFPIA), small and medium-sized enterprises (SMEs) and academia for the development of novel, more efficacious treatments for chronic pain of neuropathic origin. NGN-PET is a project launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership (PPP) for health research worldwide co-funded by the EU and the European pharmaceutical industry.

 

Chemotargets and the Josep Carreras Leukemia Research Institute sign collaboration agreement Blog Post

The Josep Carreras Leukemia Research Institute (IJC) announced today that it has entered into a collaboration agreement with the IMIM’s spin-off Chemotargets, located at the Barcelona Science Park.  The aim of the collaboration is to further understand the mechanism of action of some active hits in leukemia discovered at IJC, and exploit this information to identify new chemical entities with improved pharmacology and safety profiles using Chemotargets’ precision modeling platform. 

 

Tomàs Marquès-Bonet awarded by the Howard Hughes Medical Institute Blog Post

Researcher Tomàs Marquès-Bonet, director of the Institute for Evolutionary Biology (IBE), and leader of the Comparative Genomics group at CNAG-CRG at the Barcelona Science Park, has been awarded the International Early Career Award by the Howard Hughes Medical Institute (HHMI, USA). He will receive $ 650,000 spread over five years, starting in September 2017. A total of 1,600 researchers from around the world attended the call, of which only 41 were selected. To date, only 5 investigators in Spain have received this recognition.